HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.

<h4>Introduction</h4>Guidelines advocate the treatment of HCV in all HIV/HCV co-infected individuals. The aim of this randomized, open-label study (ClinicalTrials.gov identifier: NCT02707601; https://clinicaltrials.gov/ct2/show/NCT02707601) was to evaluate the safety/efficacy of ledipasv...

Full description

Bibliographic Details
Main Authors: Gregory D Huhn, Moti Ramgopal, Mamta K Jain, Federico Hinestrosa, David M Asmuth, Jihad Slim, Deborah Goldstein, Shauna Applin, Julie H Ryu, Shuping Jiang, Stephanie Cox, Moupali Das, Thai Nguyen-Cleary, David Piontkowsky, Bill Guyer, Lorenzo Rossaro, Richard H Haubrich
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0224875

Internet

https://doi.org/10.1371/journal.pone.0224875

Similar Items